Today’s Stock Alert: Today Ultragenyx Pharmaceutical Inc Stock Rises

Today's Stock Alert: Today Ultragenyx Pharmaceutical Inc Stock Rises

The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is a huge mover today! About 500,510 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has declined 22.06% since April 4, 2016 and is downtrending. It has underperformed by 23.15% the S&P500.
The move comes after 7 months positive chart setup for the $2.12B company. It was reported on Nov, 4 by Barchart.com. We have $78.04 PT which if reached, will make NASDAQ:RARE worth $848.00M more.

Analysts await Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to report earnings on November, 14. They expect $-1.58 EPS, down 53.40% or $0.55 from last year’s $-1.03 per share. After $-1.46 actual EPS reported by Ultragenyx Pharmaceutical Inc for the previous quarter, Wall Street now forecasts 8.22% negative EPS growth.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Ratings Coverage

Out of 12 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 12 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ultragenyx Pharmaceutical Inc has been the topic of 20 analyst reports since July 27, 2015 according to StockzIntelligence Inc. Leerink Swann initiated Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) rating on Friday, February 19. Leerink Swann has “Outperform” rating and $80 price target. The company was initiated on Tuesday, June 28 by Bank of America. The firm has “Outperform” rating given on Tuesday, September 1 by Raymond James. Citigroup upgraded the shares of RARE in a report on Tuesday, January 12 to “Neutral” rating. The rating was initiated by Citigroup on Thursday, September 3 with “Sell”. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. Morgan Stanley downgraded it to “Equal Weight” rating and $126 target price in Monday, July 27 report. Wedbush maintained Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on Tuesday, May 10 with “Outperform” rating. The stock of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has “Buy” rating given on Friday, October 23 by Jefferies. As per Tuesday, February 9, the company rating was initiated by H.C. Wainwright.

According to Zacks Investment Research, “Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company’s product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California.”

Insitutional Activity: The institutional sentiment decreased to 0.97 in Q2 2016. Its down 0.12, from 1.09 in 2016Q1. The ratio dropped, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
The New York-based Cornerstone Capital Mngmt Limited Liability Company has invested 0% in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Clearbridge Invs Ltd has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Moreover, Northern Tru has 0.01% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 425,694 shares. Blackrock Gru Ltd accumulated 0% or 22,930 shares. Federated Pa has 443,050 shares for 0.06% of their US portfolio. Manufacturers Life Insur Co The has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). Columbia Prns L L C Invest Mngmt reported 5,882 shares or 0.02% of all its holdings. Moreover, Principal Gp Incorporated has 0% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 66,892 shares. Moreover, Price T Rowe Associates Md has 0.02% invested in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) for 1.59M shares. Highbridge Cap Management Lc holds 7,304 shares or 0.01% of its portfolio. Columbia Wanger Asset Mngmt Limited Liability Company accumulated 863,392 shares or 0.49% of the stock. Gam Ag holds 0.06% or 75,800 shares in its portfolio. Pub Employees Retirement Association Of Colorado accumulated 0% or 6,773 shares. Credit Suisse Ag has 141,187 shares for 0.01% of their US portfolio. Lazard Asset Mngmt Limited Liability has 24,750 shares for 0% of their US portfolio.

More news for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) were recently published by: Nasdaq.com, which released: “Ultragenyx Pharmaceutical Enters Oversold Territory (RARE)” on November 03, 2016. Investorplace.com‘s article titled: “3 Stocks to Watch on Thursday: Monsanto Company (MON), Ultragenyx …” and published on July 14, 2016 is yet another important article.

RARE Company Profile

Ultragenyx Pharmaceutical Inc., incorporated on June 13, 2011, is a clinical-stage biopharmaceutical company. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment